Social network for physicians SERMO announced the new Drug Ratings tool, which is the first and only global peer-to-peer prescription drug review system sourced exclusively from verified licensed physicians. It is designed to provide physicians with a deeper look at treatments before they prescribe them to support better treatment decisions.
Integrated into the SERMO social network, Drug Ratings gives physicians a clinical decision support tool where they can research, rate, and share their direct experience on the efficacy, safety, tolerability, accessibility, and adherence of specific drugs in real time. Official clinical trial data and product monographs are only half of the story — aggregate real-world experience from peers is the other half.
“This new tool offers a large community of physicians access to see the subtle issues involved with medications. Ratings will be an invaluable part of physicians’ daily routines. This level of transparency will enhance patient care,” said Dr. Heidi Moawad, a neurologist who participated in the beta testing of the Drug Ratings tool.
A recent SERMO polling of more than 4,500 doctors, conducted before the tool was released to members, has found that 74 percent of doctors believe drug reviews from other doctors would help inform their prescribing choices. Also 83 percent reported that the opinion or feedback of another physician has changed their perception of a drug, and 52 percent feel they don’t have all the information they would want about a drug before prescribing.
In addition, 80 percent of those surveyed trust recommendations of a very large number of real-world doctors with product experience over the recommendations of a very small number of key opinion leaders/academics; and 69 percent feel that doctors have a better understanding of how a drug works in the real world than pharmaceutical companies, insurance companies, or patients.
When it comes to other information sources, 77 percent rely on Amazon reviews to help inform buying choices, while 91 percent think that pharmaceutical marketing “spins” information about drugs to show them in a more positive light at least some of the time.
“Drug Ratings is transparent and democratized medical knowledge from and for doctors around the world,” Peter Kirk, CEO of SERMO, said in a statement. “Manufacturers and insurers have been calling the shots when it comes to the evaluation and adoption of drugs in recent decades; Drug Ratings levels the playing field. It gives doctors back their voice in this important discussion. Consumers have Amazon, Yelp or Trip Advisor. Now physicians have peer-to-peer Drug Ratings.”
The Drug Ratings tool is said to be particularly valuable for physicians researching new-to-market drugs, as open discussions on how certain drugs have performed in the real world for early adopters can be quickly reviewed, disseminated, and adopted more broadly.